Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AT-101 + Bicalutamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AT-101||R-(-)-gossypol acetic acid |AT101||BCL2 Family Inhibitor 6||AT-101 is a pan-BCL2 inhibitor that inhibits the anti-apoptotic proteins BCL2, BCL-XL, and MCL1, potentially resulting in increased tumor cell apoptosis and decreased cell proliferation (PMID: 26089640, PMID: 16611409, PMID: 31388792).|
|Bicalutamide||Casodex||Hormone - Anti-androgens 27||Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||no benefit||AT-101 + Bicalutamide||Phase I||Actionable||In a Phase I trial, the combination of AT-101 and Casodex (bicalutamide) resulted in an undetectable PSA in 31% (17/55) of patients with castration resistant prostate cancer, however, the percentage did not reach the prespecified level and thus, the theraputic combination will not be pursued further (PMID: 26476589).||26476589|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|